Giiant Pharma Inc. is focused on developing innovative drug therapeutics specifically designed for the treatment of inflammatory bowel diseases (IBD). The company employs a proprietary technology known as Gastrointestinal-Induced Anti-inflammatory (GIANT) technology, which utilizes the gut microbiota to bioactivate and release active drug substances at targeted locations within the lower gastrointestinal tract. This approach allows for orally delivered, gut-restricted small molecules that achieve high concentrations in the colonic area while minimizing systemic absorption, thereby enhancing drug tolerability and safety for patients. Their lead candidate, GT-2108, is a microbiota-activated phosphodiesterase-4 (PDE4) inhibitor prodrug that exemplifies this precision delivery strategy.

Giiant Pharma's mission is to improve the therapeutic index of pharmacologic treatments for IBD by ensuring that drug activation occurs only at the site of inflammation. The company’s Precision Delivery platform is designed to prevent premature activation of prodrugs in the upper gastrointestinal tract, allowing for localized treatment that targets inflammatory processes without systemic side effects. By focusing on tissue-specific delivery and bioactivation, Giiant Pharma aims to provide safer, patient-tailored therapies that can significantly enhance the quality of life for individuals suffering from chronic gastrointestinal conditions.

Canada

Giiant is a preclinical-stage biotech company, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.

Giiant Pharma Inc.

Company Details